Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Non-Current Deffered Revenue (2017 - 2025)

Historic Non-Current Deffered Revenue for Protagonist Therapeutics (PTGX) over the last 6 years, with Q3 2025 value amounting to $2.8 million.

  • Protagonist Therapeutics' Non-Current Deffered Revenue fell 8311.22% to $2.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.8 million, marking a year-over-year decrease of 8311.22%. This contributed to the annual value of $11.7 million for FY2024, which is N/A changed from last year.
  • Protagonist Therapeutics' Non-Current Deffered Revenue amounted to $2.8 million in Q3 2025, which was down 8311.22% from $5.4 million recorded in Q2 2025.
  • Protagonist Therapeutics' 5-year Non-Current Deffered Revenue high stood at $28.9 million for Q1 2024, and its period low was $2.8 million during Q3 2025.